Citations

Clear

14 citation(s) found for "Park, Jun".

Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study
Park, Sun Jae , Kim, Minseo , Jeong, Seogsong , Choi, Seulggie , Kim, Hye Jun , Song, Jihun, Lee, Jaewon, Lee, Ji Won, Jeong, Jihui, Yu, Jiwon , Park, Young Jun , Kim, Hye Jun , Choi, Jiwon , Chang, Jooyoung , Oh, Yun Hwan , Ahn, Joseph C , Park, Sang Min , Lee, Ji‐Won , Chang, Jooyoung , Ahn, Joseph , Park, Sang Min

Mayo Clinic

Journal of the American Heart Association | October 22, 2025 | Volume: 14 | Issue: 20 | Pages: No page available

10.1161/jaha.124.035888 | PMID 41120818 Get It

Background Antibiotic use may alter gut microbiota, which could be associated with various diseases, including cardiovascular disease (CVD). Accordingly, further epidemiological evidence is needed to clarify the potential risk of CVD associated with antibiotic exposure. We evaluated the association between long‐term antibiotic exposure and CVD risk in South Korea. Methods and Results This nationwide retrospective cohort study used data from the Korean National Health Insurance Service database. A total of 2 159 965 individuals aged 40 to 79 years who had no history of antibiotic prescriptions from 2004 to 2005 were included and followed through December 31, 2021. Antibiotic exposure was defined as the cumulative days of antibiotic prescriptions from 2006 to 2010. The primary end point was incident CVD with 2 or more days of hospitalization from 2011 to 2021. Adjusted hazard ratios (aHR) and 95% CIs for CVD according to antibiotic exposure were estimated using multivariable Cox proportional hazards models, adjusting for a range of covariates. Longer cumulative antibiotic prescription days were associated with an increased risk of CVD. The aHRs for CVD associated with 1 to 14, 15 to 90, 91 to 180, 181 to 364, and ≥365 days of antibiotic exposure were 0.98 (95% CI, 0.96–1.01), 1.01 (95% CI, 0.99–1.03), 1.05 (95% CI, 1.03–1.08), 1.06 (95% CI, 1.04–1.09), and 1.10 (95% CI, 1.07–1.13) compared with those with no antibiotic prescriptions. Conclusions In this large population‐based cohort study of Korean adults, long‐term antibiotic exposure may be associated with a higher risk of CVD. Further research is warranted to establish causality and elucidate the underlying mechanisms for this association.
Revised Process for ACNS Guidelines Development
Andrade, Edgard , Galloway, Gloria, Hyslop, Ann , Selioutski, Olga , Arnold, Susan T., Drislane, Frank W. , Gloss, David , Marashly, Ahmad , Nuwer, Mark R., Sabau, Dragos , Shahid, Asim, Tatum, William O. , Vengrow, Michael, Wusthoff, Courtney J. , Quraishi, Imran H , Andrade, Edgard , Wusthoff, Courtney J , Selioutski, Olga , Hyslop, Ann , Sinha, Saurabh Kumar , Arnold, Susan T., Arya, Ravindra , Bagić, Anto , Hani, Abeer J. , Kobayashi, Eliane , Park, Jun , San‐Juan, Daniel , Shahid, Asim, Skjei, Karen L. , Vengrow, Michael

Mayo Clinic

Journal of Clinical Neurophysiology | January 30, 2025 | Volume: 42 | Issue: 2 | Pages: 95-100

10.1097/wnp.0000000000001133 | PMID 39883486 Get It

Summary: The development of clinical practice guidelines is an evolving field. In response to the need for consistent, evidence-based medical practice, the American Clinical Neurophysiology Society identified the need to update the Society's guideline development process. The American Clinical Neurophysiology Society Guidelines Committee created an action plan with the goal of improving transparency and rigor for future guidelines and bringing existing guidelines to current standards. This article provides an overview of the new American Clinical Neurophysiology Society standards for the creation of clinical guidance documents, including clinical guidelines, technical standards, and consensus statements. This process is rooted in the importance of clinical guidance documents and their significance in the context of current behests for updated standards for practicing clinical neurophysiology. The need and rationale for updating the guideline development process from its prior state were described. The updated American Clinical Neurophysiology Society categories for clinical guidance and recommendations were defined and compared. Finally, the new process is summarized, focusing on methodologies, authorship, and conflicts of interest.
Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma
Gogineni, Emile , Sells, Blake , Dibs, Khaled , Jhawar, Sachin R. , Limbach, Abberly Lott , Konieczkowski, David J. , Jun, Sung , Baliga, Sujith , Mitchell, Darrion , Grecula, J.C., Bonomi, Marcelo , Bhateja, Priyanka, Old, Matthew , Seim, Nolan B. , Kang, Stephen Y. , Rocco, James W. , Chakravarti, Arnab , Blakaj, Dukagjin , Gamez, Mauricio E. , Sells, Blake E , Ma, Sung J , Mitchell, Darrion L , Bonomi, Marcelo , Bhateja, Priyanka , Jhawar, Sachin R , Chakravarti, Arnab , Haring, Catherine T. , Zhu, Simeng

Mayo Clinic

Cancers | March 19, 2024 | Volume: 16 | Issue: 6 | Pages: 1204

10.3390/cancers16061204 | PMID 38539538 Get It

Background: Salivary duct carcinomas (SDC) are a rare and aggressive subtype of salivary gland neoplasm. They can present with distinct immunoprofiles, such as androgen receptor (AR) and HER-2/Neu-positivity. To date, no consensus exists on how to best manage this entity. Methods: All patients diagnosed with nonmetastatic AR+ SDC of the parotid from 2013 to 2019 treated with curative intent were included. Immunologic tumor profiling was conducted using 24 distinct markers. Kaplan–Meier analyses were used to estimate locoregional recurrence (LRR), distant control, and overall survival (OS). Results: Fifteen patients were included. Nine (60%) patients presented with T4 disease and eight (53%) had positive ipsilateral cervical lymphadenopathy. Ten (67%) patients underwent trimodality therapy, including surgery followed by adjuvant radiation and concurrent systemic therapy. The median follow-up was 5.5 years (interquartile range, 4.8–6.1). The estimated 5-year rates of LRR, distant progression, and OS were 6%, 13%, and 87%, respectively. Conclusion: Despite only including AR+ SDC of the parotid, immunoprofiles, such as expression of HER-2, were highly variable, highlighting the potential to tailor systemic regimens based on individual histologic profiles in the future. Studies with larger patient numbers using tumor-specific molecular profiling and tumor heterogeneity analyses are justified to better understand the biology of these tumors. Molecularly informed treatment approaches, including the potential use of AR- and HER-2/Neu-directed therapies upfront in the definitive setting, may hold future promise to further improve outcomes for these patients.
National Survey of Oncologists' Knowledge, Attitudes, and Practice Behaviors: Caring for Cancer Patients Experiencing Incarceration
Iwai, Yoshiko , Li, Jian , Isaacs, Tamia J., Jun, Sung , Elmore, Shekinah N C , Kamran, Sophia C. , Oladeru, Oluwadamilola T.

Mayo Clinic

Journal of Correctional Health Care | March 11, 2024 | Volume: 30 | Issue: 2 | Pages: 97-106

10.1089/jchc.23.08.0064 | PMID 38466954 Get It

Effect of Infraorbital and/or Infratrochlear Nerve Blocks on Postoperative Care in Patients with Septorhinoplasty: A Meta-Analysis
Kim, Do Hyun , Park, Jun‐Beom , Kim, Sung Won , Stybayeva, Gulnaz , Hwang, Se Hwan , Stybayeya, Gulnaz , Kim, Do Hyun , Hwang, Se Hwan

Mayo Clinic

Medicina | September 14, 2023 | Volume: 59 | Issue: 9 | Pages: 1659

10.3390/medicina59091659 | PMID 37763778 Get It

Background and Objectives: Through a comprehensive meta-analysis of the pertinent literature, this study evaluated the utility and efficacy of perioperative infraorbital and/or infratrochlear nerve blocks in reducing postoperative pain and related morbidities in patients undergoing septorhinoplasty. Materials and Methods: We reviewed studies retrieved from the PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases up to August 2023. The analysis included a selection of seven articles that compared a treatment group receiving perioperative infraorbital and/or infratrochlear nerve blocks with a control group that either received a placebo or no treatment. The evaluated outcomes covered parameters such as postoperative pain, the amount and frequency of analgesic medication administration, the incidence of postoperative nausea and vomiting, as well as the manifestation of emergence agitation. Results: The treatment group displayed a significant reduction in postoperative pain (mean difference = −1.7236 [−2.6825; −0.7646], I2 = 98.8%), as well as a significant decrease in both the amount (standardized mean difference = −2.4629 [−3.8042; −1.1216], I2 = 93.0%) and frequency (odds ratio = 0.3584 [0.1383; 0.9287], I2 = 59.7%) of analgesic medication use compared to the control. The incidence of emergence agitation (odds ratio = 0.2040 [0.0907; 0.4590], I2 = 0.0%) was notably lower in the treatment group. The incidence of postoperative nausea and vomiting (odds ratio = 0.5393 [0.1309; 2.2218], I2 = 60.4%) showed a trend towards reduction, although it was not statistically significant. While no adverse effects reaching statistical significance were reported in the analyzed studies, hematoma (proportional rate = 0.2133 [0.0905; 0.4250], I2 = 76.9%) and edema (proportional rate = 0.1935 [0.1048; 0.3296], I2 = 57.2%) after blocks appeared at rates of approximately 20%. Conclusions: Infraorbital and/or infratrochlear nerve blocks for septorhinoplasty effectively reduce postoperative pain and emergence agitation without notable adverse outcomes.
Left atrial reservoir strain as a novel predictor of new-onset atrial fibrillation in light-chain-type cardiac amyloidosis
Choi, You‐Jung , Kim, Darae , Rhee, Tea-Min, Lee, Hyun‐Jung , Park, Jun‐Bean , Lee, Seung‐Pyo , Kim, Yong-Jin , Jeon, Eun‐Seok , Oh, Jae K. , Choi, Jin‐Oh , Kim, Hyung‐Kwan , Jeon, Eun-Seok , Kim, Hyung-Kwan , Rhee, Tea-Min, Chang, Sung‐A

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 14, 2023 | Volume: 24 | Issue: 6 | Pages: 751-758

10.1093/ehjci/jeac269 | PMID 36637873 Get It

Abstract Aims To investigate whether left arterial reservoir strain (LASr) could predict new-onset atrial fibrillation (NOAF) in patients with light-chain-type cardiac amyloidosis (ALCA). Methods and results This study enrolled 427 patients with CA from two tertiary centres between 2005 and 2019. LASr was measured using a vendor-independent analysis programme. The primary outcome was NOAF. A total of 287 patients with ALCA were included [median age 63.0 (56.0–70.0) years, 53.3% male]. The median LASr was 13.9% (10.5–20.8%). During the median follow-up of 0.85 years, AF occurred in 34 patients (11.8%). In the receiver operating characteristics curve analysis, the optimal cut-off of LASr for predicting NOAF was 14.4%. Patients with LASr ≤14.4% had a higher risk of NOAF than those with LASr >14.4% (18.1% vs. 5.1%, P < 0.010). In the multivariate analysis adjusting for confounding factors, including left arterial volume index and left ventricular global longitudinal strain (LV-GLS), higher LASr (%) was independently associated with lower risk for NOAF [adjusted hazard ratio (aHR): 0.936, 95% confidence interval (95% CI): 0.879–0.997, P = 0.039]. Furthermore, LASr ≤14.4% was an independent predictor for NOAF (aHR: 3.370, 95% CI: 1.337–8.492, P = 0.010). This remained true after accounting for all-cause death as a competing risk. Compared with Model 1 (LV-GLS) and Model 2 (LV-GLS plus LAVI), Model 3, including LASr showed a better reclassification ability for predicting NOAF (net reclassification index = 0.735, P < 0.001 compared with Model 1; net reclassification index = 0.514, P = 0.003 compared with Model 2). Conclusion LASr was an independent predictor of NOAF in patients with ALCA.
Management of Infantile Spasms During the COVID-19 Pandemic
Mytinger, John R. , Baumer, Fiona M. , Ciliberto, Michael A. , Cohen, Bruce H. , Dlugos, Dennis , Harini, Chellamani , Joshi, Sucheta M. , Keator, Cynthia, McGoldrick, Patricia E. , Nickels, Katherine , Park, Jun , Pasupuleti, Archana, Shahid, Asim, Shellhaas, Renée A. , Shrey, Daniel W. , Singh, Rani K. , Yozawitz, Elissa , Yuskaitis, Christopher J. , Waugh, Jeff L. , Baumer, Fiona M , Park, Jun T , Patel, Anup D , Singh, Rani K , Pearl, Phillip L , Shellhaas, Renée A , Yozawitz, Elissa G , Nickels, Katherine C , Grinspan, Zachary M. , Hussain, Shaun A. , Knupp, Kelly G. , Patel, Anup D. , Wolf, Steven M. , Pearl, Phillip L.

Mayo Clinic

Journal of Child Neurology | June 24, 2020 | Volume: 35 | Issue: 12 | Pages: 828-834

10.1177/0883073820933739 | PMID 32576057 Get It

Circumstances of the COVID-19 pandemic have mandated a change to standard management of infantile spasms. On April 6, 2020, the Child Neurology Society issued an online statement of immediate recommendations to streamline diagnosis and treatment of infantile spasms with utilization of telemedicine, outpatient studies, and selection of first-line oral therapies as initial treatment. The rationale for the recommendations and specific guidance including follow-up assessment are provided in this manuscript. These recommendations are indicated as enduring if intended to outlast the pandemic, and limited if intended only for the pandemic health care crisis but may be applicable to future disruptions of health care delivery.
Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy
Park, Jun‐Bean , Lee, Heesun , Yoon, Yeonyee E. , Park, Hyo Eun , Choi, Su‐Yeon , Kim, Yong-Jin , Ommen, Steve R. , Kim, Hyung‐Kwan , Kim, Hyung-Kwan , Kim, Dahye , Hwang, In‐Chang , Yoon, Yeonyee Elizabeth , Cho, Goo‐Yeong , Han, Kyungdo

Mayo Clinic

European Journal of Preventive Cardiology | December 2, 2019 | Volume: 27 | Issue: 17 | Pages: 1849-1857

10.1177/2047487319889714 | PMID 31787021 Get It

Aims We sought to investigate the association of obesity and metabolic health status with the incidence of clinical hypertrophic cardiomyopathy (HCM) diagnosis in the general population. Our goal was to identify modifiable risk factors to attenuate clinical expression of HCM, enabling management evolution from a mostly passive strategy of risk stratification to a proactive strategy of modifying disease expression. Methods Using nationwide population-based data from the Korean National Health Insurance Service, 28,679,891 people who were free of prevalent HCM and who underwent health examinations between 2009 and 2015 were followed until 31 December 2016. The primary outcome was clinical HCM that was defined as incident diagnosis of HCM during the follow-up, after a blanking period of 12 months. Results Over a median follow-up of 5.2 years, 0.027% (n = 7851) of the study participants were diagnosed as incident HCM. The incidence rate per 1000 person-years was 0.059. A significant association was found between body mass index (BMI) and the incidence of clinical HCM after multivariate adjustment, with a hazard ratio per 1 kg/m2 increase in BMI of 1.063 (95% confidence interval 1.051–1.075). Metabolically unhealthy participants had a greater incidence of HCM than metabolically healthy participants, regardless of obesity status. The effect of BMI was more pronounced in several subgroups, including participants with no hypertension, those aged less than 65 years and men. Conclusion We found that individuals with obesity and/or metabolic abnormalities had a significantly higher incidence of clinical HCM diagnosis than their counterparts. Efforts to manage obesity and metabolic abnormalities may be important in modifying clinical expression of HCM.
Validation of the hypertrophic cardiomyopathy risk-sudden cardiac death calculator in Asians
Kim, Hyung‐Kwan , Lee, Sang‐Chol , Park, Jun‐Bean , Kim, Yong‐Jin , Ommen, Steve R. , Kim, Hyung-Kwan , Ommen, Steve, Choi, You‐Jung , Moon, Inki , Park, Jiesuck , Sohn, Dae‐Won

Mayo Clinic

Heart | August 5, 2019 | Volume: 105 | Issue: 24 | Pages: 1892-1897

10.1136/heartjnl-2019-315160 | PMID 31383719 Get It

Objective The hypertrophic cardiomyopathy (HCM) risk-sudden cardiac death (SCD) calculator endorsed by the 2014 European Society of Cardiology has not been independently validated in the Asians. We aimed to investigate whether the HCM Risk-SCD calculator effectively predicts SCD in Korean HCM population. Methods An observational, longitudinal cohort study was performed in 730 patients with HCM from 2007 to 2017. The primary endpoint was a composite of SCD and appropriate implantable cardioverter-defibrillator (ICD) therapy. Results During a follow-up period of 4288 person-years, 16 (2.2%) patients reached the primary endpoint. This validation study revealed a calibration slope of 0.892 and C-statistics of 0.718. The primary endpoint occurred in 1.1% (7/615), 4.6% (3/65) and 12.0% (6/50) of low-risk, intermediate-risk and high-risk groups, respectively. Although most patients (85.2%) without the primary endpoint were classified into the low-risk group, 7 of 11 SCD (63.6%) occurred in the low-risk group. In univariable and multivariable analysis, sex (woman) was significantly associated with the primary endpoint and emerged as independent predictor. The addition of sex to the HCM Risk-SCD calculator significantly improved the predictive value of the primary endpoint (net reclassification improvement 0.557, p=0.015). Conclusions In the Korean HCM population, the HCM Risk-SCD calculator had a high negative predictive value and accuracy for predicting SCD or appropriate ICD therapy, but misclassified a few patients experiencing the primary endpoint as low-risk or intermediate-risk groups.